Researchers have modified a herpes simplex virus (HSV-1) that stimulates the immune system to attack glioblastoma cells. A single dose of the modified virus increased T-cell, natural killer cell, and myeloid cell responses in the tumor microenvironment and increased the overall survival in preclinical models.
Included as a benefit
Members of Applied Microbiology International have unlimited access to The Microbiologist as a benefit of membership. Just sign in with your usual membership credentials.
Find out more about how to join.
FREE
Want to read more before deciding on a subscription? It only takes a minute to sign up for a free account and you’ll get to enjoy more free content each month.
3.75 per month / £35 annually
Get unlimited access to The Microbiologist.